TREA

79358924 - SSHLNP

Follow

Information

  • Trademark
  • 79358924
  • Serial Number
    79358924
  • Registration Number
    7483833
  • Filing Date
    May 13, 2022
    2 years ago
  • Registration Date
    August 27, 2024
    4 months ago
  • Transaction Date
    November 27, 2024
    a month ago
  • Status Date
    August 27, 2024
    4 months ago
  • Published for Opposition Date
    June 11, 2024
    6 months ago
  • Location Date
    August 26, 2024
    4 months ago
  • Status Code
    700
  • Current Location
    FILE REPOSITORY (FRANCONIA)
    Employee Name
    MAJCHER HARTNETT, MEGAN
  • Attorney Docket Number
    008814.00013
    Attorney Name
    Evi T. Christou
  • Owners
Information
Mark Drawing Code
4
Mark Identification
SSHLNP
Case File Statements
  • GS0051: Nanoparticle-based pharmaceutical substances and nanoparticle-based pharmaceutical preparations for medical, veterinary and pharmaceutical purposes namely drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle substances and silicon nanoparticle preparations for medical, veterinary and pharmaceutical purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines, porous silicon nanoparticle substances and porous silicon nanoparticle preparations for medical, veterinary and pharmaceutical purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticle substances and lipid nanoparticle preparations for medical, veterinary and pharmaceutical purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticle substances and silicon-lipid nanoparticle preparations for medical, veterinary and pharmaceutical purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for medical, veterinary and pharmaceutical purposes, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for medical, veterinary and pharmaceutical purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for medical, veterinary and pharmaceutical purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; nanoparticle substances and nanoparticle preparations for pharmaceutical, medical and veterinary diagnosis purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle substances and silicon nanoparticle preparations for pharmaceutical, medical and veterinary diagnosis purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; porous silicon nanoparticle substances and porous silicon nanoparticle preparations for pharmaceutical, medical and veterinary diagnosis purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticle substances and lipid nanoparticle preparations for pharmaceutical, medical and veterinary diagnosis purposes namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticle substances and silicon-lipid nanoparticle preparations for pharmaceutical, medical and veterinary diagnosis purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for pharmaceutical, medical and veterinary diagnosis purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for pharmaceutical, medical and veterinary diagnosis purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for pharmaceutical, medical and veterinary diagnosis purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; nanoparticle substances and nanoparticle preparations for medical, veterinary and pharmaceutical treatment purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle substances and silicon nanoparticle preparations for medical, veterinary and pharmaceutical treatment purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; porous silicon nanoparticle substances and porous silicon nanoparticle preparations for medical, veterinary and pharmaceutical treatment purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticle substances and lipid nanoparticle preparations for medical, veterinary and pharmaceutical treatment purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticle substances and lipid nanoparticle preparations for medical, veterinary and pharmaceutical treatment purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for medical, veterinary and pharmaceutical treatment purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for medical, veterinary and pharmaceutical treatment purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for medical, veterinary and pharmaceutical treatment purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; drug delivery agents, namely, pharmaceutical nanoparticle preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances ; drug delivery agents, namely, pharmaceutical silicon nanoparticle preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; drug delivery agents, namely, pharmaceutical porous silicon nanoparticle preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; drug delivery agents, namely, lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; drug delivery agents, namely, silicon-lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; drug delivery agents, namely, silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; drug delivery agents, namely, silicon-stabilised lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; drug delivery agents, namely, stabilised lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; pharmaceutical nanoparticle preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; pharmaceutical silicon nanoparticle preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; pharmaceutical porous silicon nanoparticle preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticles being pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticles being pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles being pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; pharmaceutical preparations for stabilising nucleic acids; pharmaceutical nanoparticle preparations for stabilising nucleic acids; pharmaceutical silicon nanoparticle preparations for stabilising nucleic acids; pharmaceutical porous silicon nanoparticle preparations for stabilising nucleic acids; lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; silicon-lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; pharmaceutical preparations for stabilising nucleic acid-lipid complexes; pharmaceutical nanoparticle preparations for stabilising nucleic acid-lipid complexes; pharmaceutical silicon nanoparticle preparations for stabilising nucleic acid-lipid complexes; pharmaceutical porous silicon nanoparticle preparations for stabilising nucleic acid-lipid complexes; lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; silicon-lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid- lipid complexes; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical nanoparticle preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical silicon nanoparticle preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical porous silicon nanoparticle preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; lipid nanoparticle materials being pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; silicon-lipid nanoparticle materials being pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical preparations for controlled release and transfection of nucleic acids; pharmaceutical nanoparticle preparations for controlled release and transfection of nucleic acids; pharmaceutical silicon nanoparticle preparations for controlled release and transfection of nucleic acids; pharmaceutical porous silicon nanoparticle preparations for controlled release and transfection of nucleic acids; lipid nanoparticle materials being pharmaceutical preparations for controlled release and transfection of nucleic acids; silicon-lipid nanoparticle materials being pharmaceutical preparations for controlled release and transfection of nucleic acids; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for controlled release and transfection of nucleic acids; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and transfection of nucleic acids; stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and transfection of nucleic acids
  • GS0011: Nanoparticle substances and nanoparticles for use in industry, science and research, namely, silicon; silicon for use in industry, science and research; silicon nanoparticle materials for use in industry, science and research; porous silicon nanoparticle materials for use in industry, science and research; lipid nanoparticles for use in industry, science and research; silicon-lipid nanoparticles for use in industry, science and research; silicon-stabilised hybrid lipid nanoparticles for use in industry, science and research; silicon-stabilised lipid nanoparticles for use in industry, science and research; stabilised lipid nanoparticles for use in industry, science and research; chemical materials, namely, silicon for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; chemical materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; silicon-lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; chemical materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; silicon-lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; chemical materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; silicon-lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; chemical materials for stabilising of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon nanoparticle materials for stabilising of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; porous silicon nanoparticle materials for stabilising of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; lipid nanoparticle materials for stabilising of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-lipid nanoparticle materials for stabilising of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-stabilised hybrid lipid nanoparticles for stabilising of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-stabilised lipid nanoparticles for stabilising of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; stabilised lipid nanoparticles for stabilising of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; chemical materials for stabilising nucleic acids for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon nanoparticle materials for stabilising nucleic acids for use in the manufacture of pharmaceuticals, cosmetics and chemicals; porous silicon nanoparticle materials for stabilising nucleic acids for use in the manufacture of pharmaceuticals, cosmetics and chemicals; lipid nanoparticle materials for stabilising nucleic acids for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-lipid nanoparticle materials for stabilising nucleic acids for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-stabilised hybrid lipid nanoparticles for stabilising nucleic acids for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-stabilised lipid nanoparticles for stabilising nucleic acids for use in the manufacture of pharmaceuticals, cosmetics and chemicals; stabilised lipid nanoparticles for stabilising nucleic acids for use in the manufacture of pharmaceuticals, cosmetics and chemicals; chemical materials for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon nanoparticle materials for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticals, cosmetics and chemicals; porous silicon nanoparticle materials for stabilising of nucleic acid-lipid complexes for use in the manufacture of pharmaceuticals, cosmetics and chemicals; lipid nanoparticle materials for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-lipid nanoparticle materials for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-stabilised hybrid lipid nanoparticles for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon- stabilised lipid nanoparticles for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticals, cosmetics and chemicals; stabilised lipid nanoparticles for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticals, cosmetics and chemicals
Case File Event Statements
  • 12/30/2022 - a year ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR
  • 1/3/2023 - a year ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 1/7/2023 - a year ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 3/3/2023 - a year ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 3/6/2023 - a year ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 3/7/2023 - a year ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 4/26/2023 - a year ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 4/26/2023 - a year ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 5/17/2023 - a year ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 10/24/2023 - a year ago
    10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 10/24/2023 - a year ago
    11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 10/24/2023 - a year ago
    12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 11/27/2023 - a year ago
    13 - FINAL REFUSAL WRITTEN Type: CNFR
  • 11/27/2023 - a year ago
    14 - FINAL REFUSAL E-MAILED Type: GNFR
  • 11/27/2023 - a year ago
    15 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 4/11/2024 - 8 months ago
    18 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 4/11/2024 - 8 months ago
    17 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 5/9/2024 - 7 months ago
    19 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 5/22/2024 - 7 months ago
    20 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 6/11/2024 - 6 months ago
    23 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 4/11/2024 - 8 months ago
    16 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR
  • 6/7/2024 - 6 months ago
    22 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 6/7/2024 - 6 months ago
    21 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR
  • 6/11/2024 - 6 months ago
    24 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 6/30/2024 - 6 months ago
    25 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX
  • 8/27/2024 - 4 months ago
    27 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 11/27/2024 - a month ago
    28 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 8/27/2024 - 4 months ago
    26 - REGISTERED-PRINCIPAL REGISTER Type: R.PR